HOPES

NCT04253561 📎

Regimen

Experimental
Inetetamab 6 mg/kg (loading 8 mg/kg) IV q3w + vinorelbine 25 mg/m2 IV d1, d8.
Control
Trastuzumab 6 mg/kg (loading 8 mg/kg) IV q3w + vinorelbine 25 mg/m2 IV d1, d8.

Population

HER2-positive metastatic breast cancer, first-line treatment-naive for advanced disease; stratified by trastuzumab (neo)adjuvant exposure and visceral involvement.

Key finding

HOPES established inetetamab (first Chinese-innovated anti-HER2 monoclonal antibody, not biosimilar) + vinorelbine as 1L option for HER2+ MBC. NMPA approved June 2020. Provided domestic alternative to trastuzumab before pyrotinib dominance.

Timeline

    Guideline citations

    • NCCN BREAST